Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Isabelle Moulon"'
Autor:
Ivana Silva, Giulia Gabrielli, Juan Garcia Burgos, Isabelle Moulon, Gonzalo Calvo Rojas, Ulrich Jaeger, Rosa Giuliani
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
The article shows that the input given by healthcare professionals (HCPs) adds value to the regulatory processes surrounding the development, authorisation, and monitoring of a medicine, but is also an instrument for accountability, trust, mutual exc
Externí odkaz:
https://doaj.org/article/17f4b82d413b4ad68f8995bfc0a89266
Autor:
Gert van Valkenhoef, Beatriz Flores, Hans L. Hillege, Douwe Postmus, Francesco Pignatti, Eric Low, Maria Mavris, Isabelle Moulon, Tomas Salmonsson, Nathalie Bere, Jayne Galinsky, Sarah Richard
Publikováno v:
The Oncologist, 23(1), 44-51. ALPHAMED PRESS
The Oncologist
The Oncologist
The objectives of this study were to ascertain the treatment preferences of patients with multiple myeloma, considering benefits and risks of particular cancer treatments, and to illustrate how such data may be used to estimate patients' acceptance o
Autor:
Hans L. Hillege, Tomas Salmonson, Francesco Pignatti, Isabelle Moulon, Bettina Ryll, Douwe Postmus, Maria Mavris, Ananda Plate, Hans-Georg Eichler, Nathalie Bere
Publikováno v:
Clinical Pharmacology & Therapeutics, 99(5), 548-554. Nature Publishing Group
Currently, patient preference studies are not required to be included in marketing authorization applications to regulatory authorities, and the role and methodology for such studies have not been agreed upon. The European Medicines Agency (EMA) cond
Autor:
Fernand Sauer, Isabelle Moulon
Publikováno v:
Pharmaceuticals Policy & Law. 1999, Vol. 1 Issue 1, p9. 15p.
Autor:
Nikos Dedes, Isabelle Moulon
Publikováno v:
Journal of Ambulatory Care Management. 33:190-197
Since the European Medicines Agency was created in 1995, it has engaged in dialogue with its various stakeholders, including patients and other representatives of civil society. The establishment of the Patients' and Consumers' Working Party represen
Autor:
Spiros Vamvakas, Bo Aronsson, George Wade, Isabelle Moulon, Patrick Le Courtois, Nick Gate, Francesco Pignatti
Publikováno v:
European Journal of Clinical Pharmacology. 58:573-580
Objective. To study the issues raised during the review of drug applications submitted to the European Medicines Evaluation Agency for approval in the European Union and to identify important predictors of outcome. Methods. All consecutive applicatio
Autor:
Isabelle Moulonguet, Sylvie Fraitag
Publikováno v:
Dermatopathology, Vol 8, Iss 3, Pp 315-336 (2021)
Panniculitides form a heterogenous group of inflammatory diseases that involve the subcutaneous adipose tissue. These disorders are rare in children and have many aetiologies. As in adults, the panniculitis can be the primary process in a systemic di
Externí odkaz:
https://doaj.org/article/bc7b60177f4343a79fbcd9675ad22233
Autor:
Isabelle Moulon, Francesco Pignatti, Nirosha Amerasinghe, Alexis Nolte, Daniel Gustafsson, Marisa Papaluca Amati, Patrick Le Courtois
Publikováno v:
Journal of Biomedicine and Biotechnology
Journal of Biomedicine and Biotechnology, Vol 2003, Iss 1, Pp 3-8 (2003)
Journal of Biomedicine and Biotechnology, Vol 2003, Iss 1, Pp 3-8 (2003)
The evaluation of quality, safety, and efficacy of medicinal products by the European Medicines Evaluation Agency (EMEA) via the centralized procedure is the only available regulatory procedure for obtaining marketing authorization for gene therapy (
Autor:
Irene Papadouli, Francesco Pignatti, Bo Aronsson, Spiros Vamvakas, Isabelle Moulon, George Wade, Marisa Papaluca, Patrick Le Courtois
Publikováno v:
Critical reviews in oncology/hematology. 42(2)
The evaluation of quality, safety and efficacy of medicinal products by regulatory agencies is a necessary step for obtaining marketing authorisation in the European Union (EU). The objective of this paper is to outline some key aspects of the EU reg
Autor:
Hélène Mascitti, Adèle De Masson, Florence Brunet-Possenti, Jean-David Bouaziz, Pauline Laly, Nadim Mourad, Jean-Michel Garrigues, Sara Laurent-Roussel, Bénédicte Cavelier-Balloy, Isabelle Moulonguet, Cristina Leschi, Samia Mourah, Martine Bagot, Céleste Lebbé, Nicole Basset-Seguin
Publikováno v:
Dermatology and Therapy, Vol 9, Iss 2, Pp 383-388 (2019)
Abstract Introduction Keratoacanthomas (KA) are common cutaneous skin tumors originating from the hair follicles. Unlike squamous cell carcinoma, KA can regress spontaneously and have a benign evolution. Solitary KA is the most common form but famili
Externí odkaz:
https://doaj.org/article/a68ccc68eedf40f395d33e0110b20d55